226 related articles for article (PubMed ID: 32729092)
1. Real-world experience of lenvatinib in patients with advanced anaplastic thyroid cancer.
Kim M; Ahn J; Song DE; Yoon JH; Kang HC; Lim DJ; Kim WG; Kim TY; Kim WB; Shong YK; Jeon MJ; Kim BH
Endocrine; 2021 Feb; 71(2):427-433. PubMed ID: 32729092
[TBL] [Abstract][Full Text] [Related]
2. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer.
Iñiguez-Ariza NM; Ryder MM; Hilger CR; Bible KC
Thyroid; 2017 Jul; 27(7):923-927. PubMed ID: 28471306
[TBL] [Abstract][Full Text] [Related]
3. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.
Takahashi S; Kiyota N; Yamazaki T; Chayahara N; Nakano K; Inagaki L; Toda K; Enokida T; Minami H; Imamura Y; Fukuda N; Sasaki T; Suzuki T; Ikezawa H; Dutcus CE; Tahara M
Future Oncol; 2019 Mar; 15(7):717-726. PubMed ID: 30638399
[TBL] [Abstract][Full Text] [Related]
4. Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma.
Iyer PC; Dadu R; Ferrarotto R; Busaidy NL; Habra MA; Zafereo M; Gross N; Hess KR; Gule-Monroe M; Williams MD; Cabanillas ME
Thyroid; 2018 Jan; 28(1):79-87. PubMed ID: 29161986
[TBL] [Abstract][Full Text] [Related]
5. Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma.
Dierks C; Seufert J; Aumann K; Ruf J; Klein C; Kiefer S; Rassner M; Boerries M; Zielke A; la Rosee P; Meyer PT; Kroiss M; Weißenberger C; Schumacher T; Metzger P; Weiss H; Smaxwil C; Laubner K; Duyster J; von Bubnoff N; Miething C; Thomusch O
Thyroid; 2021 Jul; 31(7):1076-1085. PubMed ID: 33509020
[No Abstract] [Full Text] [Related]
6. [Efficacy and Safety of Lenvatinib for Unresectable Anaplastic Thyroid Cancer].
Yamazaki H; Shimizu S; Iwasaki H; Yoshida T; Suganuma N; Yamanaka T; Kojima I; Masudo K; Toda S; Nakayama H; Masuda M
Gan To Kagaku Ryoho; 2017 Aug; 44(8):695-697. PubMed ID: 28860443
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE).
Higashiyama T; Sugino K; Hara H; Ito KI; Nakashima N; Onoda N; Tori M; Katoh H; Kiyota N; Ota I; Suganuma N; Hibi Y; Nemoto T; Takahashi S; Yane K; Ioji T; Kojima S; Kaneda H; Sugitani I; Tahara M
Eur J Cancer; 2022 Sep; 173():210-218. PubMed ID: 35932627
[TBL] [Abstract][Full Text] [Related]
8. Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer.
Wirth LJ; Brose MS; Sherman EJ; Licitra L; Schlumberger M; Sherman SI; Bible KC; Robinson B; Rodien P; Godbert Y; De La Fouchardiere C; Newbold K; Nutting C; Misir S; Xie R; Almonte A; Ye W; Cabanillas ME
J Clin Oncol; 2021 Jul; 39(21):2359-2366. PubMed ID: 33961488
[TBL] [Abstract][Full Text] [Related]
9. Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis.
Kim SY; Kim SM; Kim JW; Lee IJ; Jeon TJ; Chang H; Kim BW; Lee YS; Chang HS; Park CS
Front Endocrinol (Lausanne); 2020; 11():599. PubMed ID: 32982983
[No Abstract] [Full Text] [Related]
10. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
[TBL] [Abstract][Full Text] [Related]
11. Limited efficacy of lenvatinib in heavily pretreated anaplastic thyroid cancer: a French overview.
Sparano C; Godbert Y; Attard M; Do Cao C; Zerdoud S; Roudaut N; Joly C; Berdelou A; Hadoux J; Lamartina L; Schlumberger M; Leboulleux S
Endocr Relat Cancer; 2021 Jan; 28(1):15-26. PubMed ID: 33112817
[TBL] [Abstract][Full Text] [Related]
12. Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan.
Takahashi S; Tahara M; Ito K; Tori M; Kiyota N; Yoshida K; Sakata Y; Yoshida A
Adv Ther; 2020 Sep; 37(9):3850-3862. PubMed ID: 32676927
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Lenvatinib in Anaplastic Thyroid Carcinoma: A Meta-Analysis.
Huang D; Zhang J; Zheng X; Gao M
Front Endocrinol (Lausanne); 2022; 13():920857. PubMed ID: 35846304
[TBL] [Abstract][Full Text] [Related]
14. First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study.
Soll D; Bischoff P; Frisch A; Jensen M; Karadeniz Z; Mogl MT; Horst D; Penzkofer T; Spranger J; Keilholz U; Mai K
BMC Endocr Disord; 2024 Feb; 24(1):25. PubMed ID: 38383419
[TBL] [Abstract][Full Text] [Related]
15. Long-term management of lenvatinib-treated thyroid cancer patients: a real-life experience at a single institution.
Porcelli T; Luongo C; Sessa F; Klain M; Masone S; Troncone G; Bellevicine C; Schlumberger M; Salvatore D
Endocrine; 2021 Aug; 73(2):358-366. PubMed ID: 33537956
[TBL] [Abstract][Full Text] [Related]
16. Expression of vascular endothelial growth factor receptor 2 and clinical response to lenvatinib in patients with anaplastic thyroid cancer.
Yamazaki H; Yokose T; Hayashi H; Iwasaki H; Osanai S; Suganuma N; Nakayama H; Masudo K; Rino Y; Masuda M
Cancer Chemother Pharmacol; 2018 Oct; 82(4):649-654. PubMed ID: 30051190
[TBL] [Abstract][Full Text] [Related]
17. Real-life use of lenvatinib in patients with differentiated thyroid cancer: experience from Argentina.
Jerkovich F; Califano I; Bueno F; Carrera JM; Giglio R; Abelleira E; Pitoia F
Endocrine; 2020 Jul; 69(1):142-148. PubMed ID: 32253682
[TBL] [Abstract][Full Text] [Related]
18. Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Anaplastic Thyroid Carcinoma.
Osawa Y; Gozawa R; Koyama K; Nakayama T; Sagoh T; Sunaga H
Intern Med; 2018 Apr; 57(7):1015-1019. PubMed ID: 29225265
[TBL] [Abstract][Full Text] [Related]
19. Neutrophil-to-Lymphocyte Ratio as a Prognostic Marker for Anaplastic Thyroid Cancer Treated With Lenvatinib.
Fukuda N; Toda K; Fujiwara YU; Wang X; Ohmoto A; Urasaki T; Hayashi N; Sato Y; Nakano K; Yunokawa M; Ono M; Tomomatsu J; Mitani H; Takahashi S
In Vivo; 2020; 34(5):2859-2864. PubMed ID: 32871825
[TBL] [Abstract][Full Text] [Related]
20. Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer.
Gunda V; Gigliotti B; Ashry T; Ndishabandi D; McCarthy M; Zhou Z; Amin S; Lee KE; Stork T; Wirth L; Freeman GJ; Alessandrini A; Parangi S
Int J Cancer; 2019 May; 144(9):2266-2278. PubMed ID: 30515783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]